Cronos Group stock analysis
Want to see TSE:CRON full AI Analyst Report?
Cronos Group (CRON) Stock Price & Analysis
CRON Stock Chart & Stats
- Day’s Range
- CAD 4.84 - CAD 5.03
- 52-Week Range
- CAD 3.23 - CAD 5.47
- Previous Close
- CAD 5.10
- Volume
- N/A
- Average Volume (3M)
- 141.67K
- Market Cap
- CAD 1.78B
- Enterprise Value
- CAD 761.19M
- Total Cash (Recent Filing)
- CAD 741.17M
- Total Debt (Recent Filing)
- CAD 1.21M
- Price to Earnings (P/E)
- 21.3
- Beta
- 1.21
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- 0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Profitability
The latest results show a meaningful improvement in both scale and profitability, with revenue growth accompanied by strong gross and operating margins. If these economics persist, Cronos can fund product development and market expansion internally while strengthening earnings power.
Brand And Market-Share Leadership
Sustained category leadership gives Cronos valuable consumer recognition and distribution relevance in competitive legal cannabis markets. Leading positions across vapes and edibles can support repeat demand, improve launch visibility for new products, and reinforce the company’s branded portfolio.
Strong Liquidity And Low Leverage
An exceptionally conservative capital structure and positive cash generation provide Cronos with substantial financial flexibility. Low leverage reduces financing pressure, while internally generated cash can support capacity, innovation, acquisitions, or other strategic investments through market cycles.
Bears Say
Volatile Earnings And Cash-Flow History
The recent turnaround has not yet established a consistently durable earnings pattern. Earlier losses and negative cash flow indicate that profitability and cash conversion can weaken materially, making future performance more dependent on sustained execution and favorable operating conditions.
Ongoing Price Compression
As European cannabis markets mature and supply expands, lower realized prices could pressure revenue quality and gross margins even if volumes continue to grow. This creates a lasting challenge for maintaining profitability and extracting attractive returns from international expansion.
Regulatory And Permitting Constraints
Regulatory restrictions can limit which products Cronos sells, how efficiently it distributes them, and how quickly it expands its European footprint. Slow approvals also reduce near-term control over market access, delaying the contribution of planned international growth initiatives.
Cronos Group News
CRON FAQ
What was Cronos Group’s price range in the past 12 months?
What is Cronos Group’s market cap?
When is Cronos Group’s upcoming earnings report date?
How were Cronos Group’s earnings last quarter?
Is Cronos Group overvalued?
Does Cronos Group pay dividends?
What is Cronos Group’s EPS estimate?
How many shares outstanding does Cronos Group have?
What happened to Cronos Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cronos Group?
What is the TipRanks Smart Score and how is it calculated?
Cronos Group Stock Smart Score
Company Description
Cronos Group
Cronos Group Inc. functions as a diversified global cannabinoid enterprise. Within the United States, it manufactures, promotes, and distributes a variety of hemp-derived supplements and cosmetic products. These items are available under its Lord Jones and Happy Dance brands through online sales, traditional retail, and hospitality partner networks. The company also plays a significant role in the cultivation, production, and commercialization of cannabis and cannabis-infused products for both medicinal and adult-use sectors. Its comprehensive product offerings encompass dried cannabis flower, pre-rolled joints, edibles, concentrated forms, and cannabis extracts. These are distributed via wholesale partnerships and direct-to-consumer channels, prominently featuring its wellness platform, PEACE NATURALS, and its adult-use brand, Spinach. Moreover, Cronos Group exports dried cannabis and cannabis oils to international markets including Germany, Israel, and Australia. Established in 2012, the company maintains its corporate headquarters in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Michael Ryan Gorenstein
- Employees
- 610
- Website
- www.thecronosgroup.com
- Address
- 4491 Concession Road 12, Stayner, ON, L0M 1S0, CA
Cronos Group (CRON) Earnings & Revenues
CRON Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Cronos reported substantial year-over-year growth and records across net revenue, gross profit, and Adjusted EBITDA, supported by strong performance in Israel, Canada, Germany, and other international markets. The company also highlighted brand share gains, product innovation, a strong cash position, and the completed CanAdelaar acquisition. The main challenges were seasonal Canadian softness, lumpy international shipment timing, price compression, tight Canadian flower supply, higher operating expenses, and regulatory and permitting constraints in the Netherlands, but these did not outweigh the reported operating momentum.
View all TSE:CRON earnings summariesCRON Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 5 | 2 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 12 | 0 | 0 |
